Top aesthetic clinics are adding the AOS system to their microneedling and RF protocols and seeing immediate uptake in add-on revenue. 3D-culture, xenofree, pharmaceutical-grade — here's the science behind why it works, and what makes it different from every other exosome on the market.
Every decision in the production process leaves a molecular signature in the final vial. These are the three that matter most.
When MSCs are grown in 2D on flat plastic, they flatten. Their cytoskeleton reorganizes. Their secretome shifts away from what those cells do in the body. In 3D spheroid culture, MSCs restore native cell-cell contact, activate hypoxic core signaling, and produce 3–5x more exosomes with richer cargo.
Haraszti et al. 2018; Thomi et al. 2019; Cesarz & Tamama 2016
Read the researchConventional culture uses fetal bovine serum at 10–40% of media volume. FBS introduces thousands of bovine proteins that contaminate the exosome preparation. Xenofree manufacturing replaces all animal-derived components with defined pharmaceutical-grade alternatives — eliminating xenogeneic contamination and delivering batch-to-batch consistency FBS-based processes cannot achieve.
Read the researchMSCs at passage 2–4 are in peak secretory activity. By passage 8+, senescence-associated secretory phenotype (SASP) emerges — a shift toward inflammatory markers and away from the growth factors and miRNAs associated with healthy MSC biology. The exosomes carry the molecular signature of the cells that made them. Cell age matters.
Read the researchThe AOS system combines the exosome vial (Core) with a post-treatment recovery vehicle (Shield). Each component is formulated for a defined role in the clinical workflow.
The exosome vial. Applied during or after treatment depending on modality.
Recovery vehicle. Applied post-treatment in RF microneedling, laser, and chemical peel protocols.
Culture geometry changes how MSCs behave. 3D spheroids restore native cell-cell contact and signaling suppressed in 2D monolayer. Published research shows 3–5x higher yield and measurably different cargo — including higher concentrations of growth factors, HSPs, and immunomodulatory miRNAs compared to 2D-derived preparations.
No animal-derived components — no fetal bovine serum. Eliminates xenogeneic protein contamination and delivers defined composition. Fetal bovine serum contains thousands of bovine proteins that co-purify with exosomes and cannot be reliably removed by standard isolation methods. Xenofree processes replace FBS with human platelet lysate or fully synthetic defined media.
MSCs accumulate replicative stress with each passage. Research documents declining secretory activity and SASP emergence at higher passages. Low-passage cells (P2–4) produce exosomes reflecting peak secretory activity — higher growth factor concentrations, more diverse miRNA payload, and lower levels of senescence-associated inflammatory markers.
Exosome preparations in aesthetic contexts are regulated differently from pharmaceutical drugs. This site presents educational content about exosome biology and manufacturing science. No drug claims are made. Practitioners should consult current FDA guidance regarding the regulatory status of exosome preparations in their jurisdiction.
Use our provider directory. All listed clinics are verified AOS system users who have completed clinical protocol training. Search by zip code and radius to find a provider near you.